17,261 trials
Cushing Disease
Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders
Primary Sclerosing Cholangitis
Primary: Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels. — 3 Participants
Hypertension
Primary: Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF) — -11.4; -13.1; -12.5; -18.7 mmHg
Spinal Cord Injury · Acute Spinal Cord Injury · Bone Loss
Primary: Percent Change in Bone Mass Density (BMD) in the Hip — -2.21; -12.82 percent change in bone mass density — p=0.05
Acromegaly
Primary: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response by Dose Class — 20; 28.6; 14.3; 23.1 percentage of…
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
Hypertension
Primary: Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in…
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Change From Baseline In Serum LDH Levels At Day 28 — 1416; 444.3; -971.7 international units per liter (IU/L)
Ankylosing Spondylitis (AS)
Primary: Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14 — 25.5; 51.6 percentage of participants — p=<0.001
Select Advanced Malignancies · Kidney Cancer · Clear Cell Renal Cell Carcinoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose-escalation Phase — 4; 5; 3; 3…
Phase 1: Pain Management · Phase 2: Pain Management
Primary: Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol — 0; 0; 0; 1 participants
Postoperative Pain
Primary: Mean Pain Intensity on Movement AUC (Time Normalized Area Under the Curve) During the Period 0 to 72 Hours Post-dose. — 5.35; 5.81 score on a scale — p=0.303
Alzheimer Disease
Primary: Change From Baseline in CSF Abeta42 — 4.8; 12.5; 16.2 pg/mL — p=0.087
Postoperative Pain
Primary: Pain Intensity (PI) — 4.15; 4.46; 4.27 score on a scale — p=0.467
Muscular Atrophy, Spinal
Primary: Hammersmith Functional Motor Scale Expanded (HFMSE) Summary Statistics and Mixed Model Analysis — 0.208; -0.583 Overall Score — p=0.0083